PROTAC-based androgen receptor degrader program (VRise Therapeutics)

N/A

Report date: 2025/01/26 19:35:08
NME

Base Information

Drug NamePROTAC-based androgen receptor degrader program (VRise Therapeutics)
Drug Alias NameAndrogen Receptor Degrader Program (VRise Therapeutics Inc)androgen receptor degrader program (PROTAC) (VRise Therapeutics)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAndrogen Receptor degraders
TargetsAndrogen Receptor
Therapy Area/IndicationsHormone-Resistant Prostate NeoplasmsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesVrise Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesVrise Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsHormone-Resistant Prostate NeoplasmsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A